Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw)
Person responsible for CTC programme: Dr hab. n med. Iwona Ługowska
Hospital Overview
The Maria Skłodowska-Curie National Research Institute of Oncology (MSCI) in Warsaw stands as a comprehensive cancer center. The Institute has branches in Gliwice, and Krakow and with Warsaw Campus accommodate approximately 25% of all cancer patients in Poland (over 130,000 hospitalized cancer patients, conducting 680,000 outpatient consultations, and diagnosing 50,000 new patients annually). The institute manages over 650 clinical trials (including 80 early-phase trials) focused on oncology.
The main MSCI campus has two buildings – research and clinical where each floor is a cancer-specific department (Department of Bone/Soft Tissue Sarcoma and Melanoma, Department of Central Nervous System Tumours, Department of Gynaecological Oncology, Department of Urological Cancer, Department of Lung Cancer & Thoracic Tumours, Department of Brest Cancer & Reconstructive Surgery, Department of Lymphoma, Department of Gastrointestinal Cancer, Department of Head & Neck Cancer, Department of Endocrine Cancer & Nuclear Medicine, Department of Cancer & Cardio-Oncology Diagnostics; Department of Oncology and Radiotherapy and Department of Oncological Surgery and Neuroendocrine Tumors).
In addition, there are Early Phase Clinical Trial Department, Day-One Hospital, Outpatient Clinics, the Hyperthermia Department, the Centre for Excellence in Precision Oncology, and CART Facility (under development). MSCI is a leader of the National Cancer Strategy, the National Oncology Network.
CTC programmes offered
1. The use of immunotherapy in combination with radical treatment methods |
|
Discipline: | Medical Oncology |
Programme mentor: |
Dr hab.med. Magdalena Knetki-Wroblewska |
Duration: | 3 months |
Type: | Visiting Observership |
Language requirements: | English |
Programme description: |
This program explores the integration of immunotherapy with radical treatment methods—such as surgery, radiotherapy, and chemoradiotherapy—in the management of various cancers (sarcoma, urological cancer, lung cancer and breast cancer). The aim is to facilitate the aquisition of expertise in optimizing therapeutic strategies that combine immune-based approaches with curative-intent treatments, enhancing patient outcomes while minimizing toxicity. Key focus areas include:
The program is designed for oncology professionals interested in advancing their knowledge and clinical practice in multidisciplinary cancer treatment, with an emphasis on innovation, evidence-based care, and translational
|
2. The use of targeted molecular therapies in combination with surgical treatment and radical radiotherapy |
|
Discipline: | Medical Oncology |
Programme mentor: | Dr hab. med. Adam Płużański |
Duration: | 3 months |
Type: | Visiting Observership |
Language requirements: | English |
Programme description: |
This program focuses on the integration of targeted molecular therapies with surgical treatment and radical radiotherapy in the management of various cancers. It aims to provide healthcare professionals with in-depth knowledge and practical insights into combining these advanced treatment modalities to optimize patient outcomes. Key focus areas include:
The program is designed for oncology professionals interested in advancing their knowledge and clinical practice in multidisciplinary cancer treatment, with an emphasis on innovation, evidence-based care, and translational research.
|
3. Approach to Patients with Oligoprogression using stereotactic radiotherapy |
|
Discipline: | Medical Oncology |
Programme mentor: | To be decided |
Duration: | 3 months |
Type: | Visiting Observership |
Language requirements: | English |
Programme description: |
This program focuses on the management of patients with oligoprogression, a condition where limited progression of cancer occurs in a small number of sites despite systemic treatment. It explores the role of stereotactic radiotherapy (SRT) as a highly precise treatment option aimed at controlling localized disease progression while maintaining the benefits of systemic therapies. Key areas of focus include:
This program is designed for oncologists, radiologists, and medical professionals involved in the treatment of cancer patients, providing advanced insights into the integration of stereotactic radiotherapy with modern systemic therapies to improve patient care and outcomes.
|
4. Comprehensive Laboratory Training in Molecular and Translational Cancer Research |
|
Discipline: | Experimental oncology |
Programme mentor: |
Prof. Dr hab. Michał Mikula |
Duration | 3 months |
Type: | Visiting Observership |
Language requirements: | English |
Programme description: |
This intensive 12-week laboratory program offers a comprehensive introduction to the core techniques and analytical methods used in molecular and translational cancer research. Structured across three thematic months, participant will progress from mastering foundation cell culture and nucleic acid techniques to applying advanced methods in genomics, proteomics, and in vivo models. Participatnt will gain hands-on experience in culturing human cancer cell lines, isolating nucleic acids, performing qPCR, transfection of cancer cells and methylation assays. The course further includes extensive training in protein isolation, mass spectrometry, and Western blotting, as well as molecular cloning and bacterial expression systems. The final module introduces metabolomics (via GC-MS and Seahorse assays) and practival animal experimentation under FELASA guidelines, providing critical link between molecular methods and translational applications. By the end of the program, trainees will have acquired a robust technical skill set essential for preclinical cancer research and be well-prepared for academic or industry-based biomedical research roles. |